Miraculin Can Contribute to a Reduction in Inflammatory Biomarkers and Cachexia in Malnourished Patients with Cancer and Taste Disorders

Miraculin Can Contribute to a Reduction in Inflammatory Biomarkers and Cachexia in Malnourished Patients with Cancer and Taste Disorders

<b>Background:</b> In 2022, there were an estimated 20 million new cancer cases and 9.7 million deaths. The number of new cancer cases is expected to rise to over 35 million by 2050, marking a 75% increase from 2022 levels. Twenty to eighty-six percent of cancer patients suffer from tast...

Full description

Saved in:
Bibliographic Details
Main Authors: Ana Isabel Álvarez-Mercado, Bricia López-Plaza, Julio Plaza-Diaz, Lucía Arcos-Castellanos, Francisco Javier Ruiz-Ojeda, Marco Brandimonte-Hernández, Jaime Feliú-Batlle, Thomas Hummel, Samara Palma-Milla, Ángel Gil
Format: Article
Language:English
Published: MDPI AG 2025-04-01
Series:Pharmaceuticals
Subjects:
cachexia
cancer
DMB
miraculin
dysgeusia
inflammation
Online Access:https://www.mdpi.com/1424-8247/18/5/622
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items